Nicht aus der Schweiz? Besuchen Sie lehmanns.de

Novel Antischizophrenia Treatments

Mark A. Geyer, Gerhard Gross (Herausgeber)

Buch | Hardcover
X, 458 Seiten
2012 | 2012
Springer Berlin (Verlag)
978-3-642-25757-5 (ISBN)
CHF 589,95 inkl. MwSt
  • Versand in 10-20 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
This volume tries to put current therapy - achievements, shortcomings, remaining medical needs - and emerging new targets into the context of increasing knowledge regarding the genetic and neurodevelopmental contributions to the pathophysiology of schizophrenia. Some of the chapters also deal with respective experimental and clinical methodology, biomarkers, and translational aspects of drug development. The volume concentrates on reviewing the ongoing research attempting to identify novel treatments for the cognitive deficits and negative symptoms of schizophrenia, which are not treated adequately by current antipsychotic medications.

Preface.- Clinical instruments to evaluate and guide treatment in schizophrenia.- Cognitive deficits in schizophrenia- Muscarinic mechanisms in psychotic disorders.- Nicotinic mechanisms in psychotic disorders.- GABAergic circuits in schizophrenia: targets for new treatments in schizophrenia.- Inhibitors of glycine transport as potential new treatments in schizophrenia.- The role of glutamate in schizophrenia.- Metabotropic glutamate receptors as targets for new treatments in schizophrenia.- 5-HT2C agonism as a principle for new treatments in schizophrenia.- The role of dopamine D3 receptors for antipsychotic activity and cognitive functions.- Phosphodiesterase inhibitors as potential new treatments in schizophrenia.- Disease modifying approaches to schizophrenia.- A novel therapeutic strategy: medication-enhancement of cognitive therapies in schizophrenia.- Transgenic animals reflecting aspects of schizophrenia.- Behavioral animal models of pro-cognitive treatments for schizophrenia.

From the reviews:

"The target audience ... is primarily researchers in the field of psychopharmacology of psychosis as well as interested psychiatrists and psychologists. ... This book will provide readers with the current research issues in the psychopharmacology of schizophrenia from a 'one disease' perspective." (Michael Joel Schrift, Doody's Book Reviews, March, 2013)

Erscheint lt. Verlag 2.10.2012
Reihe/Serie Handbook of Experimental Pharmacology
Zusatzinfo X, 458 p.
Verlagsort Berlin
Sprache englisch
Maße 155 x 235 mm
Gewicht 818 g
Themenwelt Geisteswissenschaften Psychologie Biopsychologie / Neurowissenschaften
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Medizinische Fachgebiete Psychiatrie / Psychotherapie
Medizin / Pharmazie Pflege
Medizin / Pharmazie Pharmazie PTA / PKA
Schlagworte Cognition • neurotransmitters • Psychopharmacology • Psychopharmakologie / Psychopharmaka • Schizophrenia • Schizophrenie
ISBN-10 3-642-25757-7 / 3642257577
ISBN-13 978-3-642-25757-5 / 9783642257575
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
Grundlagen, Klinik, Rehabilitation

von Georg Goldenberg; Jennifer Randerath

Buch | Softcover (2024)
Urban & Fischer in Elsevier (Verlag)
CHF 78,40
Grundlagen, Klinik, Therapie und Verlauf der …

von Hans-Christoph Steinhausen; Manfred Döpfner …

Buch | Softcover (2024)
Kohlhammer (Verlag)
CHF 117,60